Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 17, 2022 01:00 ET | Source: VALNEVA

Valneva annonce la nomination de Dipal Patel en tant que Chief Commercial Officer

Saint-Herblain (France), 17 octobre 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd’hui la nomination de Dipal Patel comme Chief Commercial...
November 17, 2022 01:00 ET | Source: VALNEVA

Valneva Appoints Dipal Patel as Chief Commercial Officer

Saint-Herblain (France), November 17, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dipal Patel as Chief Commercial Officer...
November 16, 2022 09:00 ET | Source: Visiongain Reports Ltd

Global Anti-Infective Vaccines Market is projected to grow at a CAGR of 12.51% by 2032: Visiongain Reports Ltd

Visiongain has published a new report entitled Anti-Infective Vaccines Market 2022-2032 - which includes profiles of Anti-infective Vaccines and Forecasts Market Segment by Disease Type {Bacterial...
November 14, 2022 06:08 ET | Source: ReportLinker

The Global Mono Vaccine Market is expected to grow by $2.8 bn during 2022-2026, accelerating at a CAGR of 5.16% during the forecast period

New York, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Mono Vaccine Market 2022-2026" - https://www.reportlinker.com/p06359950/?utm_source=GNW Our...
November 10, 2022 07:00 ET | Source: Altimmune, Inc

Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update

Topline 24-week data from Phase 1b trial in subjects with non-alcoholic fatty liver disease (NAFLD) expected mid-December 2022 Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected Q1...
November 10, 2022 01:00 ET | Source: VALNEVA

Valneva publie ses résultats financiers pour les neuf premiers mois de l’exercice 2022 et fait un point sur ses activités

Chiffre d’affaires total de €249,9 millions sur les neuf premiers mois de 2022, multiplié par près de 3,5 fois par rapport à 2021 €74,4 millions de ventes de produits (contre €45,5 millions sur les...
November 10, 2022 01:00 ET | Source: VALNEVA

Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates

Total nine-month revenues of €249.9 million, a ~ 3.5-fold increase compared to 2021 Product sales of €74.4 million (vs €45.5 million in the first nine months of 2021) driven by a continued recovery...
November 07, 2022 11:45 ET | Source: VALNEVA

Valneva fera une présentation et participera à des réunions investisseurs lors de la Jefferies Healthcare Conference de Londres

Saint-Herblain (France), le 7 novembre 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd'hui que son Chief Executive Officer, Thomas...
November 07, 2022 11:45 ET | Source: VALNEVA

Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

Saint-Herblain (France), November 7, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its Chief Executive Officer Thomas Lingelbach and Chief...
November 04, 2022 13:00 ET | Source: VALNEVA

VALNEVA - Déclaration d’actions et de droits de vote : 31 octobre 2022

VALNEVA Déclaration d’actions et de droits de vote 31 octobre 2022__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du...